We have some exciting team news to start 2024. We are announcing two new appointments to our leadership team – starting with Nell Montgomery our new CEO.

Nell – an executive coach, psychotherapist and former investment banker – has been Interim CEO since September 2023. Nell enjoyed an executive coaching career, including co-founding Aesara Partners, and ten-years in investment banking at Goldman Sachs and as Managing Director and member of the Board of Investec Securities UK. She now takes the role on a permanent basis.

Nell says, “I am delighted to have been appointed CEO to lead Psychiatry UK and address the UK’s crisis in mental health. Psychiatry UK is uniquely placed to help people access the highest quality of specialist mental health support. Our online, AI-powered service enables the whole family to quickly and easily access the care they need.”

Nell continues, “Psychiatry UK is driven by the best and brightest clinical and non-clinical experts who are passionate about helping to make a difference to people’s lives. That passion and commitment is an inspiration to me.”

Meanwhile, Ben Iversen has been appointed CFO. Ben has over thirty years of experience in corporate finance, has held senior roles in finance and operations at several private UK based companies, and has been an advisor to Psychiatry UK since June 2023.

Ben says, “During my time advising the company, I have been struck by the enthusiasm and passion of the Psychiatry UK community in delivering vital services and treatment to an expanding patient population in need. The business today has come a very long way but, in my view, there is plenty more room for growth.”

Dr. Andy Montgomery, Chair of the Board and co-founder, says: “On behalf of the directors, executive team and shareholders, I am pleased to welcome Nell and Ben to lead the new phase of growth for Psychiatry UK. Nell and Ben bring a unique set of skills and extensive experience across business, healthcare and the charity sectors.”

With many more changes in the pipeline – including strengthening our core neurodiversity business, transforming our patient pathways and broadening our service to include both pharmacological and non-pharmacological therapies such as ADHD coaching – now is an exciting time for Psychiatry UK.